COMPANY

Perspective Therapeutics

HQ: Seattle, WA source · perspectivetherapeutics.com ↗ · West Coast

Keywords: oncology cancer tumors Melanoma Stage IV Pancreatic Ductal Adenocarcinoma Gastric Cancer Esophageal Cancer Colorectal Cancer Ovarian Cancer Head and Neck Cancer Sarcoma Mesothelioma Recurrent Melanoma (Skin) Metastatic Melanoma Melanoma Stage III Neuroendocrine Tumors Unresectable Neuroendocrine Tumor Metastatic Gastroenteropancreatic Neuroendocrine Tumor Bronchial Neuroendocrine Tumor Paraganglioma Pheochromocytoma Meningioma Melanoma (Skin) Uveal Melanoma Mucosal Melanoma [203Pb]VMT01 [203Pb]Pb-PSV359 [212Pb]VMT01

Location: Seattle, WA · source · Oct 1, 2026

Profile checked Oct 10, 2026

$175.0MRaised (2 yrs)4Trials (company is sponsor)

Timeline

Sep 14, 2026 Partnership Partnership / licensing announced Sep 14, 2026. Source: SEC filing. source ↗
Feb 2, 2026 Raise Follow-on offering: $175M (total, as published), announced Feb 2, 2026. Source: SEC filing. source ↗
Apr 28, 2025 Trial start Phase 1/Phase 2: Lead-212 PSV359 Therapy for Patients With Solid Tumors source ↗
Sep 27, 2023 Trial start Phase 1/Phase 2: Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors source ↗
Jun 1, 2023 Trial start Phase 1/Phase 2: MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma source ↗
Mar 5, 2021 Trial start Phase 1: Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy source ↗

Upcoming milestones

Dec 31, 2027 (ESTIMATED) · Phase 1/Phase 2 · MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma · NCT05655312
Jan 31, 2028 (ESTIMATED) · Phase 1/Phase 2 · Lead-212 PSV359 Therapy for Patients With Solid Tumors · NCT06710756
Nov 26, 2029 (ESTIMATED) · Phase 1/Phase 2 · Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors · NCT05636618

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $175.0M. Last 2 years.

Feb 2, 2026 Follow-on offering: $175M (total, as published), announced Feb 2, 2026. Source: SEC filing. source ↗
Sep 14, 2026 Partnership / licensing announced Sep 14, 2026. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT06710756	Lead-212 PSV359 Therapy for Patients With Solid Tumors	Phase 1/Phase 2	Recruiting	Apr 28, 2025	Jan 31, 2028 (estimated)
NCT05655312	MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma	Phase 1/Phase 2	Recruiting	Jun 1, 2023	Dec 31, 2027 (estimated)
NCT05636618	Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors	Phase 1/Phase 2	Recruiting	Sep 27, 2023	Nov 26, 2029 (estimated)
NCT04904120	Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy	Phase 1	Completed	Mar 5, 2021	Sep 20, 2022 (actual)